PO.TB10.07 · 肿瘤生物学
空间转录组学分析揭示Ewing肉瘤中的肿瘤细胞可塑性和多样化的肿瘤微环境
Spatial transcriptomics analysis reveals tumor cell plasticity and diverse tumor microenvironments in Ewing sarcoma
该海报暂无可下载的资料
AACR 官方页面
作者与单位 Authors & Affiliations
摘要 Abstract
中文摘要
目的
Ewing肉瘤(EwS)是一种儿童和青少年时期高度侵袭性的融合基因驱动型癌症,可发生于骨和软组织。在EwS中,肿瘤微环境(TME)由来自间充质和造血谱系的细胞类型组成。肿瘤细胞与其TME之间的复杂相互作用被认为塑造了EwS中的TME结构和肿瘤细胞可塑性。既往已有研究利用bulk RNA-seq对EwS中与融合基因相关的肿瘤细胞异质性进行表征。相比之下,由于患者样本可及性有限以及现有染色方法的局限性,Ewing肉瘤的TME在单细胞和空间水平上仍在很大程度上未被充分探索。本项目旨在描绘EwS肿瘤细胞异质性,并表征EwS肿瘤细胞与TME中细胞之间的相互作用。
方法
我们对4个EwS组织块进行了单细胞FFPE测序(scFFPEseq)。利用scFFPEseq数据,我们开发了一个包含480个基因的探针panel。这一精选组合包括细胞类型标志物、差异表达基因(DEGs)、高变基因(HVGs)、肿瘤异质性特征、通路signature以及特定的受体-配体对,可实现对基因表达的精确原位分析。随后,我们对1个整切片EwS样本和来自存档组织微阵列的137个EwS核心组进行了空间分辨单细胞转录组学分析(10x Xenium)。
结果
我们生成了一个包含138例Ewing肉瘤患者样本、共314万个细胞的空间分辨单细胞数据集。对该数据集进行的meta program分析揭示了跨样本的EwS肿瘤细胞间共享的5种转录状态。这些状态包括细胞周期、蛋白质调控、缺氧应激、干扰素反应以及高EWSR1-FLI1融合活性。EwS的TME由四种基质细胞类型和八种免疫细胞类型组成。空间分析显示,EwS肿瘤细胞状态与不同的TME细胞共定位,形成了8个反复出现的niche。在坏死区域,SPP1+巨噬细胞和NK细胞富集于缺氧肿瘤细胞附近。在有淋巴细胞浸润的区域,与C1QC+巨噬细胞的共定位与EwS肿瘤细胞中干扰素反应和JAK-STAT通路活性的增加相关。最后,空间单细胞相互作用分析提示,EwS肿瘤细胞中较低的EWSR1::FLI1 signature水平可能归因于邻近成纤维细胞刺激的FGFR1信号传导。
结论
在本项目中,我们在138例EwS患者样本中定义了5种共享的肿瘤细胞program和8个反复出现的空间邻域。发现EwS肿瘤细胞与成纤维细胞之间通过FGFR1的相互作用与较低的EWSR1::FLI1融合signature相关。这一发现将为FGFR1在EwS治疗中的潜在治疗价值提供依据。
查看英文原文 English abstract
Objective
Ewing sarcoma (EwS) is a highly aggressive fusion-driven cancer of childhood and adolescence that can arise in both bone and soft tissue.In EwS, the tumor microenvironment (TME) is composed of cell types from the mesenchymal and hematopoietic lineages. Complex interactions between tumor cells and their TME are believed to shape the TME structure and the tumor cell plasticity in EwS. There have been existing efforts to characterize the fusion related tumor cell heterogeneity in EwS using bulk RNA-seq. In contrast, the TME of Ewing sarcoma remains largely underexplored at both single-cell and spatial level due to limited accessibility to patient samples and the constraints of contemporary staining methods. The aim of this project is to chart the EwS tumor cell heterogeneity and to characterize the interaction between the EwS tumor cells and the cells from the TME.
Methods
We performed single-cell FFPE sequencing (scFFPEseq) on four EwS tissue blocks. By utilizing the scFFPEseq data, we developed a probe panel comprising 480 genes. This refined selection includes cell type markers, differentially expressed genes (DEGs), highly variable genes (HVGs), hallmarks of tumor heterogeneity, pathway signatures, and specific receptor-ligand pairs, enabling precise in situ profiling of gene expression. We then performed spatially-resolved single-cell transcriptomics (10x Xenium) on 1 whole-section EwS sample and 137 EwS core sets from archived tissue microarrays.
Results
We generated a spatially-resolved single-cell dataset of 138 Ewing sarcoma patient samples, comprising 3.14 million cells. Meta program analysis on this dataset revealed 5 transcriptional states shared among EwS tumor cells across samples. These states include cell cycle, protein regulation, hypoxic stress, interferon response and high EWSR1-FLI1 fusion activity. The EwS TME consists of four stromal cell types and eight immune cell types. Spatial analysis showed that the EwS tumor cell states co-localize with distinct TME cells, giving rise to 8 recurrent niches.In the necrotic regions, SPP1+ macrophages and NK cells are found enriched in close proximity to hypoxic tumor cells. In regions with lymphocytic infiltration, co-localization with C1QC+ macrophage is associated with increased interferon response and JAK-STAT pathway activity in the EwS tumor cells.Finally, spatial single-cell interaction analysis suggests that lower EWSR1::FLI1 signature levels in the EwS tumor cells may be attributed to FGFR1 signaling stimulated by proximal fibroblasts.
Conclusion
In this project, we defined 5 shared tumor cell programs and 8 recurrent spatial neighborhoods across 138 EwS patient samples. The interplay between EwS tumor cells and fibroblasts via FGFR1 was found to be associated with lower EWSR1::FLI1 fusion signatures. This finding will lead to a potential therapeutic value of FGFR1 in the EwS treatment.
利益披露 Disclosure
H. Luo, None..
C. Henon, None..
G. Rukhovich, None..
S. Kutschmann, None..
N. Wilhelm, None..
W. Hartmann, None..
U. Dirksen, None..
D. T. Odom, None..
T. G. Grünewald, None..
M. Gerstung, None.